V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016134 | 160007997 | 1.72 | 64.35 | Palliative (P) | 2019-11-29 | 2019-12-03 | Doxorubicin + Olaratumab | 02 | null | VINORELBINE | 100387650 |
| 160016135 | 160007998 | 1.78 | 93.2 | Palliative (P) | 2017-08-10 | 2017-08-24 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101542160 |
| 160016137 | 160007999 | 1.75 | 77.3 | Palliative (P) | 2016-03-20 | 2016-04-03 | EW EuroEwing 2012 Arm A VAI | 02 | N | MELPHALAN | 101486034 |
| 160016140 | 160008000 | 1.67 | 51.6 | Palliative (P) | 2019-08-16 | 2019-08-28 | MELPHALAN | null | null | VINORELBINE | 101675151 |
| 160016141 | 160008001 | 0 | 63 | Palliative (P) | 2018-08-16 | 2018-08-17 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 101570148 |
| 160016143 | 160008002 | 1.51 | 63.15 | Palliative (P) | 2017-10-20 | 2017-10-20 | Carboplatin + Paclitaxel (3 weekly) | null | N | CARBOPLATIN + PACLITAXEL | 101844682 |
| 160016149 | 160008003 | 1.62 | 71.05 | Palliative (P) | 2017-02-22 | 2017-02-23 | LANREOTIDE | 99 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 100670336 |
| 160016150 | 160008004 | 1.7 | 58.7 | Curative (C) | 2019-11-27 | 2019-12-04 | STS Rhabdomyosarco RMS 2005 IVADoVV | null | N | STS NON-RHABDO EPSSG 2005 IFOS DOX | 100373278 |
| 160016154 | 160008005 | 1.88 | 73.45 | Palliative (P) | 2016-10-12 | 2016-10-17 | Carboplatin AUC 6 - 10 | null | N | LIPOSOMAL DOXORUBICIN | 100806339 |
| 160016155 | 160008006 | 1.66 | 80.2 | null | 2018-04-08 | 2018-04-19 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 100008589 |
| 160016158 | 160008007 | 1.59 | 53.2 | Neo-adjuvant (N) | 2018-10-19 | 2018-10-29 | Carboplatin AUC 2 - 5 | N | N | CARBOPLATIN | 100663710 |
| 160016159 | 160008008 | 1.6 | 93.1 | Palliative (P) | 2016-11-30 | 2016-12-14 | DOXORUBICIN + IFOSFAMIDE | 02 | null | VINCRISTINE | 100202740 |
| 160016161 | 160008009 | 1.82 | 89.1 | Curative (C) | 2017-10-16 | 2017-10-24 | STS Non-Rhabdo EpSSG 2005 IVA | 01 | N | DOXORUBICIN + OLARATUMAB | 101075740 |
| 160016164 | 160008010 | 1.64 | 54.5 | Palliative (P) | 2015-07-30 | 2015-08-26 | Paclitaxel 7 day | Y | null | ABIRATERONE | 101808165 |
| 160016166 | 160008011 | 1.7 | 76.2 | Curative (C) | 2018-10-01 | 2018-10-15 | Trabectedin | 02 | N | TRIAL UNSPECIFIED | 100421690 |
| 160016169 | 160008012 | 1.66 | 96.55 | Adjuvant (A) | 2016-07-02 | 2016-07-03 | Doxorubicin + Ifosfamide | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100930302 |
| 160016170 | 160008013 | 1.52 | 58.5 | null | 2020-03-24 | 2020-03-24 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100415905 |
| 160016172 | 160008014 | 1.57 | 76.6 | Palliative (P) | 2016-08-14 | 2016-08-14 | CARBOPLATIN | N | N | CARBOPLATIN | 101857592 |
| 160016174 | 160008015 | 1.71 | 71.65 | Palliative (P) | 2017-06-23 | 2017-07-14 | IVADo | 02 | N | TRIAL UNSPECIFIED | 100048266 |
| 160016175 | 160008016 | null | 66.9 | null | 2016-04-06 | 2016-04-12 | Trial Unspecified | 02 | N | DOXORUBICIN | 100233080 |
| 160016177 | 160008017 | 1.65 | 119.9 | null | 2016-09-21 | 2016-09-28 | Liposomal Doxorubicin (Caelyx) | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100223707 |
| 160016178 | 160008018 | 1.64 | 78 | Palliative (P) | 2016-02-13 | 2016-03-03 | CARBOPLATIN + PACLITAXEL | 02 | Y | CARBOPLATIN + PACLITAXEL | 100892173 |
| 160016180 | 160008019 | 0 | 17.8 | Palliative (P) | 2019-02-25 | 2019-03-09 | Doxorubin 50mg/m2 | 2 | N | DOXORUBICIN + IFOSFAMIDE | 100269138 |
| 160016182 | 160008020 | 1.75 | 71.1 | Palliative (P) | 2017-12-23 | 2017-12-25 | Trial Unspecified | 02 | N | CARBOPLATIN + GEMCITABINE | 101057979 |
| 160016183 | 160008021 | 1.79 | 87.5 | Palliative (P) | 2017-10-18 | 2017-11-11 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 100705666 |
| 160016189 | 160008022 | 0 | 59 | Palliative (P) | 2017-04-21 | 2017-04-21 | Trial Unspecified | N | N | DOXORUBICIN + IFOSFAMIDE | 100636353 |
| 160016190 | 160008023 | 1.68 | 59 | Neo-adjuvant (N) | 2019-09-09 | 2019-09-10 | IVADo | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101398710 |
| 160016192 | 160008024 | 1.6 | 62 | null | 2020-03-25 | 2020-04-18 | Trial Unspecified | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100466954 |
| 160016193 | 160008025 | 1.64 | 78 | Palliative (P) | 2017-03-17 | 2017-04-05 | Liposomal Doxorubicin (Caelyx) | null | N | CYCLOPHOSPHAMIDE | 100964803 |
| 160016194 | 160008026 | 1.55 | 55.4 | Palliative (P) | 2017-10-03 | 2017-10-17 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101751687 |
| 160016195 | 160008027 | 1.76 | 76.95 | Curative (C) | 2019-12-24 | 2019-12-31 | null | 02 | N | TRIAL UNSPECIFIED | 101103120 |
| 160016196 | 160008028 | 1.66 | 88 | Curative (C) | 2019-06-25 | 2019-07-14 | CARBOPLATIN + ETOPOSIDE | 02 | N | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100426930 |
| 160016198 | 160008029 | 1.59 | 57.3 | Palliative (P) | 2017-07-17 | 2017-08-28 | EW EuroEwing 2012 Arm B VDC | N | N | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 100051458 |
| 160016199 | 160008030 | null | 59.6 | Neo-adjuvant (N) | 2018-06-23 | 2018-06-29 | EpSSG NRSTS 2005 | N | N | CYCLOPHOSPHAMIDE | 100912899 |
| 160016201 | 160008031 | 1.66 | 96.7 | null | 2016-11-26 | 2016-12-03 | Doxorubicin 75mg/m2 | 02 | null | DOXORUBICIN | 100777375 |
| 160016202 | 160008032 | 1.82 | 82.8 | Neo-adjuvant (N) | 2019-01-20 | 2019-01-23 | Doxorubicin + Ifosfamide | 02 | N | TRIAL | 100245376 |
| 160016203 | 160008033 | 1.82 | 69 | Curative (C) | 2019-10-30 | 2019-10-30 | null | 02 | N | CYCLOPHOSPHAMIDE + THALIDOMIDE | 101031665 |
| 160016204 | 160008034 | 1.91 | 68 | Palliative (P) | 2015-09-26 | 2015-09-27 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101284717 |
| 160016206 | 160008035 | 1.69 | 55 | null | 2016-08-10 | 2016-08-16 | Carboplatin + Paclitaxel (3 weekly) | 02 | Y | EW EUROEWING 2012 ARM B VDC | 100434623 |
| 160016207 | 160008036 | 1.72 | 72.4 | Palliative (P) | 2016-09-21 | 2016-09-21 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101420014 |
| 160016208 | 160008037 | 1.72 | 69.4 | Palliative (P) | 2016-08-13 | 2016-08-27 | ETOP 13-18 BEAT-meso Trial | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101453452 |
| 160016209 | 160008038 | 1.91 | 72.55 | Palliative (P) | 2019-11-18 | 2019-12-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100261378 |
| 160016211 | 160008039 | 1.76 | 67.3 | Palliative (P) | 2017-08-18 | 2017-08-18 | VIDE | 02 | null | STS RHABDOMYOSARCO RMS 2005 IVADOVV | 100606937 |
| 160016212 | 160008040 | 1.74 | 86 | Palliative (P) | 2019-12-28 | 2019-12-29 | Doxorubicin 75mg/m2 | 01 | N | DOXORUBICIN | 100469851 |
| 160016213 | 160008041 | null | 73.1 | null | 2019-03-28 | 2019-04-04 | Cisplatin + Pemetrexed | 01 | null | CISPLATIN + PEMETREXED | 100339011 |
| 160016214 | 160008042 | null | 75.6 | null | 2017-09-26 | 2017-10-05 | STS Non-Rhabdo EpSSG 2005 Ifos Dox | 2 | N | DOCETAXEL | 100377752 |
| 160016215 | 160008043 | 1.62 | 56.7 | Palliative (P) | 2018-04-25 | 2018-05-02 | Cyclophosphamide oral | 02 | null | LIPOSOMAL DOXORUBICIN | 101711099 |
| 160016216 | 160008044 | 1.53 | 83 | Palliative (P) | 2019-12-02 | 2019-12-02 | CARBOPLATIN + PACLITAXEL | 02 | null | CARBOPLATIN + PACLITAXEL | 100889867 |
| 160016221 | 160008045 | 1.72 | 72.05 | Palliative (P) | 2016-02-29 | 2016-03-04 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | null | PACLITAXEL | 100343119 |
| 160016227 | 160008046 | 1.82 | 64 | Palliative (P) | 2016-05-20 | 2016-06-25 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100301185 |